Similarly, affordable tirzepatide options including compounded formulations have expanded access for many patients
At present, retatrutide is primarily available within clinical trial settings
Conflict of interest Bjrn Eliasson reports personal fees (expert panels, lectures) from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mundipharma, Navamedic, NovoNordisk and RLS Global, and grants and personal fees from Sanofi, all outside the submitted work
Zydus provides a revolutionary reusable multi-dose pen device, in contrast to existing treatment choices that frequently need patients to buy many single-dose pens as they gradually titrate their dosage
You still enjoy meals, but the compulsive edge around food diminishes significantly